Protease Inhibitors

Amino Acid Sequence Z-Leu-Leu-Leu-al General description A potent, reversible, and cell-permeable proteasome inhibitor (K i = 4 nM). Reduces the degradation of ubiquitin-conjugated proteins in mammalian cells and permeable strains of yeast by the

Amino Acid Sequence Z-Leu-Leu-Leu-al General description A potent, reversible, and cell-permeable proteasome inhibitor (K i = 4 nM). Reduces the degradation of ubiquitin-conjugated proteins in mammalian cells and permeable strains of yeast by the

Biochem/physiol Actions MG-132(R) is a potent, membrane-permeable proteasome inhibitor. It induces neurite outgrowth in PC12 cells at 10 M.

MK-5172 is a novel P2-P4 quinoxaline macrocyclic HCV NS3/4a protease inhibitor currently in clinical development.

MK-5172 is a novel P2-P4 quinoxaline macrocyclic HCV NS3/4a protease inhibitor currently in clinical development.

Application ML 210 has been used as a glutathione peroxidase 4 (GPX4) inhibitor to induce ferroptosis in cancer cells. It has also been used as a GPX4 inhibitor to examine whether pharmacological inhibition of GPX4 altered prominin2 expression

Application ML 210 has been used as a glutathione peroxidase 4 (GPX4) inhibitor to induce ferroptosis in cancer cells. It has also been used as a GPX4 inhibitor to examine whether pharmacological inhibition of GPX4 altered prominin2 expression

The first identified small molecule inhibitor of BLM helicase (IC₅₀ = 1.8 &muM) that is 28-fold selective against the related helicases RECQ1, RECQ5, and E.

The first identified small molecule inhibitor of BLM helicase (IC₅₀ = 1.8 &muM) that is 28-fold selective against the related helicases RECQ1, RECQ5, and E.

The first identified small molecule inhibitor of BLM helicase (IC₅₀ = 1.8 &muM) that is 28-fold selective against the related helicases RECQ1, RECQ5, and E.

A dual inhibitor of the two mammalian forms of PLD, PLD1 and PLD2 (IC₅₀s = 6 and 20 nM, respectively) penetrates the CNS and is functional in vivo when given intraperitoneally has potential applications in oncology and virology.

A dual inhibitor of the two mammalian forms of PLD, PLD1 and PLD2 (IC₅₀s = 6 and 20 nM, respectively) penetrates the CNS and is functional in vivo when given intraperitoneally has potential applications in oncology and virology.